BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
03 Gennaio 2024 - 10:30PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that members of its
management team will present at the 42nd Annual J.P. Morgan
Healthcare Conference in San Francisco, CA on Monday, January 8 at
8:15 am PT.
To access the live webcast of BridgeBio’s presentation, please
visit the “Events & Presentations” page within the Investors
section of the BridgeBio website at http://investor.bridgebio.com.
A replay of the webcast will be available on the BridgeBio website
for 30 days following the event.
About BridgeBio Pharma, Inc.BridgeBio Pharma,
Inc. (BridgeBio) is a commercial-stage biopharmaceutical company
founded to discover, create, test, and deliver transformative
medicines to treat patients who suffer from genetic diseases and
cancers with clear genetic drivers. BridgeBio’s pipeline of
development programs ranges from early science to advanced clinical
trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers and innovators are committed to
applying advances in genetic medicine to help patients as quickly
as possible. For more information visit
bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650)-789-8220
Grafico Azioni BridgeBio Pharma (NASDAQ:BBIO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni BridgeBio Pharma (NASDAQ:BBIO)
Storico
Da Giu 2023 a Giu 2024